Cargando…

Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan

BACKGROUND: We investigated factors associated with prolonged viral clearance of SARS-CoV-2 among non-severe adult patients in Osaka, Japan. A total of 706 laboratory-confirmed COVID-19 patients were enrolled in this longitudinal observational study between 29 January 2020 and 31 May 2020, across 62...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, Emma Nakagawa, Kawachi, Haruna, Hirayama, Atsushi, Zhang, Jingwen, Murayama, Ayumi, Masui, Jun, Fujita, Satomi, Mori, Yasushi, Hirayama, Takanori, Ohara, Toshitake, Asada, Rumiko, Iso, Hiroyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647504/
https://www.ncbi.nlm.nih.gov/pubmed/34872493
http://dx.doi.org/10.1186/s12199-021-01035-y
_version_ 1784610618065551360
author Hoffman, Emma Nakagawa
Kawachi, Haruna
Hirayama, Atsushi
Zhang, Jingwen
Murayama, Ayumi
Masui, Jun
Fujita, Satomi
Mori, Yasushi
Hirayama, Takanori
Ohara, Toshitake
Asada, Rumiko
Iso, Hiroyasu
author_facet Hoffman, Emma Nakagawa
Kawachi, Haruna
Hirayama, Atsushi
Zhang, Jingwen
Murayama, Ayumi
Masui, Jun
Fujita, Satomi
Mori, Yasushi
Hirayama, Takanori
Ohara, Toshitake
Asada, Rumiko
Iso, Hiroyasu
author_sort Hoffman, Emma Nakagawa
collection PubMed
description BACKGROUND: We investigated factors associated with prolonged viral clearance of SARS-CoV-2 among non-severe adult patients in Osaka, Japan. A total of 706 laboratory-confirmed COVID-19 patients were enrolled in this longitudinal observational study between 29 January 2020 and 31 May 2020, across 62 hospitals and three non-hospital recuperation facilities. METHODS: Logistic regression analysis was performed to investigate the factors associated with prolonged (29 days: upper 25% in duration) viral clearance of SARS-CoV-2. Linear regression analysis was conducted to assess these factors 14 days after symptom onset. RESULTS: The median duration of viral clearance was 22 days from symptom onset. After adjustment for sex, age, symptoms, comorbidity, and location of recuperation, comorbidities were associated with prolonged duration: (OR, 1.77 [95% CI, 1.11–2.82]) for one, (OR, 2.47 [95% CI, 1.32–4.61]) for two or more comorbidities. Viral clearance 14 days after symptom onset was 3 days longer for one comorbidity and 4 days longer for two or more comorbidities compared to clearance when there was no comorbidity. CONCLUSION: The presence of comorbidity was a robust factor associated with a longer duration of viral clearance, extending by 3 to 4 days compared to patients with no comorbidity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12199-021-01035-y.
format Online
Article
Text
id pubmed-8647504
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86475042021-12-06 Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan Hoffman, Emma Nakagawa Kawachi, Haruna Hirayama, Atsushi Zhang, Jingwen Murayama, Ayumi Masui, Jun Fujita, Satomi Mori, Yasushi Hirayama, Takanori Ohara, Toshitake Asada, Rumiko Iso, Hiroyasu Environ Health Prev Med Research Article BACKGROUND: We investigated factors associated with prolonged viral clearance of SARS-CoV-2 among non-severe adult patients in Osaka, Japan. A total of 706 laboratory-confirmed COVID-19 patients were enrolled in this longitudinal observational study between 29 January 2020 and 31 May 2020, across 62 hospitals and three non-hospital recuperation facilities. METHODS: Logistic regression analysis was performed to investigate the factors associated with prolonged (29 days: upper 25% in duration) viral clearance of SARS-CoV-2. Linear regression analysis was conducted to assess these factors 14 days after symptom onset. RESULTS: The median duration of viral clearance was 22 days from symptom onset. After adjustment for sex, age, symptoms, comorbidity, and location of recuperation, comorbidities were associated with prolonged duration: (OR, 1.77 [95% CI, 1.11–2.82]) for one, (OR, 2.47 [95% CI, 1.32–4.61]) for two or more comorbidities. Viral clearance 14 days after symptom onset was 3 days longer for one comorbidity and 4 days longer for two or more comorbidities compared to clearance when there was no comorbidity. CONCLUSION: The presence of comorbidity was a robust factor associated with a longer duration of viral clearance, extending by 3 to 4 days compared to patients with no comorbidity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12199-021-01035-y. BioMed Central 2021-12-06 2021 /pmc/articles/PMC8647504/ /pubmed/34872493 http://dx.doi.org/10.1186/s12199-021-01035-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Hoffman, Emma Nakagawa
Kawachi, Haruna
Hirayama, Atsushi
Zhang, Jingwen
Murayama, Ayumi
Masui, Jun
Fujita, Satomi
Mori, Yasushi
Hirayama, Takanori
Ohara, Toshitake
Asada, Rumiko
Iso, Hiroyasu
Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan
title Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan
title_full Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan
title_fullStr Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan
title_full_unstemmed Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan
title_short Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan
title_sort factors associated with prolonged duration of viral clearance in non-severe sars-cov-2 patients in osaka, japan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647504/
https://www.ncbi.nlm.nih.gov/pubmed/34872493
http://dx.doi.org/10.1186/s12199-021-01035-y
work_keys_str_mv AT hoffmanemmanakagawa factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan
AT kawachiharuna factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan
AT hirayamaatsushi factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan
AT zhangjingwen factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan
AT murayamaayumi factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan
AT masuijun factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan
AT fujitasatomi factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan
AT moriyasushi factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan
AT hirayamatakanori factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan
AT oharatoshitake factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan
AT asadarumiko factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan
AT isohiroyasu factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan